Sass Jörn Oliver, Gemperle-Britschgi Corinne, Tarailo-Graovac Maja, Patel Nisha, Walter Melanie, Jordanova Albena, Alfadhel Majid, Barić Ivo, Çoker Mahmut, Damli-Huber Aynur, Faqeih Eissa Ali, García Segarra Nuria, Geraghty Michael T, Jåtun Bjørn Magne, Kalkan Uçar Sema, Kriewitz Merten, Rauchenzauner Markus, Bilić Karmen, Tournev Ivailo, Till Claudia, Sayson Bryan, Beumer Daniel, Ye Cynthia Xin, Zhang Lin-Hua, Vallance Hilary, Alkuraya Fowzan S, van Karnebeek Clara D M
Bioanalytics & Biochemistry, Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, Rheinbach, Germany; Clinical Chemistry & Biochemistry, Children's Research Center, University Children's Hospital, Zürich, Switzerland; Laboratory of Clinical Biochemistry and Metabolism, University Children's Hospital, Freiburg, Germany.
Clinical Chemistry & Biochemistry, Children's Research Center, University Children's Hospital, Zürich, Switzerland.
Mol Genet Metab. 2016 Sep;119(1-2):44-9. doi: 10.1016/j.ymgme.2016.07.008. Epub 2016 Jul 22.
Primary 5-oxoprolinuria (pyroglutamic aciduria) is caused by a genetic defect in the γ-glutamyl cycle, affecting either glutathione synthetase or 5-oxoprolinase. While several dozens of patients with glutathione synthetase deficiency have been reported, with hemolytic anemia representing the clinical key feature, 5-oxoprolinase deficiency due to OPLAH mutations is less frequent and so far has not attracted much attention. This has prompted us to investigate the clinical phenotype as well as the underlying genotype in patients from 14 families of various ethnic backgrounds who underwent diagnostic mutation analysis following the detection of 5-oxoprolinuria. In all patients with 5-oxoprolinuria studied, bi-allelic mutations in OPLAH were indicated. An autosomal recessive mode of inheritance for 5-oxoprolinase deficiency is further supported by the identification of a single mutation in all 9/14 parent sample sets investigated (except for the father of one patient whose result suggests homozygosity), and the absence of 5-oxoprolinuria in all tested heterozygotes. It is remarkable, that all 20 mutations identified were novel and private to the respective families. Clinical features were highly variable and in several sib pairs, did not segregate with 5-oxoprolinuria. Although a pathogenic role of 5-oxoprolinase deficiency remains possible, this is not supported by our findings. Additional patient ascertainment and long-term follow-up is needed to establish the benign nature of this inborn error of metabolism. It is important that all symptomatic patients with persistently elevated levels of 5-oxoproline and no obvious explanation are investigated for the genetic etiology.
原发性5-氧脯氨酸尿症(焦谷氨酸尿症)由γ-谷氨酰循环中的遗传缺陷引起,影响谷胱甘肽合成酶或5-氧脯氨酸酶。虽然已经报道了几十例谷胱甘肽合成酶缺乏症患者,溶血贫血是临床关键特征,但由于OPLAH突变导致的5-氧脯氨酸酶缺乏症较少见,迄今为止未引起太多关注。这促使我们对来自14个不同种族背景家庭的患者进行临床表型及潜在基因型研究,这些患者在检测到5-氧脯氨酸尿症后接受了诊断性突变分析。在所有研究的5-氧脯氨酸尿症患者中,均显示出OPLAH的双等位基因突变。在所有检测的14个父母样本组中的9个(除一名患者的父亲结果提示纯合子外)中均鉴定出单一突变,且所有检测的杂合子均无5-氧脯氨酸尿症,这进一步支持了5-氧脯氨酸酶缺乏症的常染色体隐性遗传模式。值得注意的是,鉴定出的所有20种突变都是各家族特有的新突变。临床特征高度可变,在几对同胞中,与5-氧脯氨酸尿症不相关。虽然5-氧脯氨酸酶缺乏症仍可能具有致病作用,但我们的研究结果并不支持这一点。需要更多患者确诊及长期随访以确定这种先天性代谢缺陷的良性性质。重要的是,对于所有5-氧脯氨酸水平持续升高且无明显原因的有症状患者,都应调查其遗传病因。